PrimeCell Overview
- Founded
-
2007

- Status
-
Private
- Employees
-
100

- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
2
- Investments
-
1
PrimeCell General Information
Description
Developer of regenerative medicine focused on discovering and clinical testing of biological drugs and medicinal technologies. The company's scientific and manufacturing infrastructure utilizes technologies to develop, process and manufacture human cell and tissue products that change genes and cells parameters to support the regeneration of human tissues and organs, thereby enabling physicians and patients with new treatments that use human cells and new materials such as nanomaterials to treat serious diseases.
Contact Information
Website
www.primecell.eu
Ownership Status
Privately Held (backing)
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Primary Office
- BioIncubator 4MEDi, University Hospital
- Dr. Slabihoudka 11
- Ostrava, 708 00
- Czech Republic
PrimeCell Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
PrimeCell Patents
PrimeCell Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3851853-A1 | Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells | Inactive | 17-Jan-2020 | 00000000000 | 0 |
EP-4090972-A1 | Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells | Pending | 17-Jan-2020 | 00000000000 | |
US-20230044560-A1 | Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells | Pending | 17-Jan-2020 | 000000000 | |
EP-3851852-A1 | Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells | Inactive | 17-Jan-2020 | 0000000000 | 0 |
EP-4090971-A1 | Method for separation of sperm with undamaged intact heads from sperm with damaged heads and somatic cells | Pending | 17-Jan-2020 | G01N33/689 |
PrimeCell Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Serhiy Forostyak Ph.D | Chief Scientific Officer | ||
Petr Koška Ph.D | Chief Executive Officer & Vice Chairman, National Cell and Tissue Centre |
PrimeCell Board Members (3)
Name | Representing | Role | Since |
---|---|---|---|
000 0000000 | PrimeCell | Member of the Board of Trustees | 000 0000 |
0000 00š00 00.0 | Self | Chief Executive Officer & Vice Chairman, National Cell and Tissue Centre | 000 0000 |
PrimeCell Signals
PrimeCell Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000á 00000 | 21-Dec-2020 | 0000000000 | 00.00 | Other Healthcare Services |
PrimeCell Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
000000á 00000 0000 | Other Healthcare Services | Ostrava, Czech Republic | 0000 |